Standout Papers

Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-W... 2005 2026 2012 2019 518
  1. Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical Study (2005)
    Philip J. Rosenfeld, C PULIAFITO et al. Ophthalmology

Immediate Impact

10 from Science/Nature 58 standout
Sub-graph 1 of 21

Citing Papers

Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study
2024 Standout
Smart Contact Lenses as Wearable Ophthalmic Devices for Disease Monitoring and Health Management
2023 Standout
2 intermediate papers

Works of Elliott M. Marcus being referenced

Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical Study
2005 Standout

Author Peers

Author Last Decade Papers Cites
Elliott M. Marcus 254 137 205 475 415 18 1.1k
C S Hoyt 59 162 71 416 385 27 1.2k
Tom Eke 183 34 355 740 201 38 1.2k
Sherry L. Fawcett 63 61 39 504 218 30 1.2k
Angelica Cerulli 67 63 20 672 413 22 1.2k
Weihua Meng 54 86 125 245 238 40 989
Raymond Garrick 60 155 65 499 154 27 1.1k
Andrew Q. McCormick 46 96 18 304 447 24 1.0k
Hedwig J. Kaiser 30 211 71 1031 465 47 1.4k
Mark Paine 32 247 109 435 142 33 1.1k
Christiane Wolf 54 29 77 220 95 37 1.3k

All Works

Loading papers...

Rankless by CCL
2026